Boehringer Ingelheim and MD Anderson Cancer Center join forces to discover new treatment approaches for pancreatic cancer
● Pancreatic ductal adenocarcinoma is one of the most lethal of cancers with no effective treatments available ● Boehringer Ingelheim and MD Anderson Cancer Center to identify new therapeutic concepts, biomarkers and develop breakthrough medicines to treat pancreatic cancer ● This collaboration underscores Boehringer Ingelheim’s focus on difficult-to-treat diseases and commitment to precision medicines
Source: Boehringer Ingelheim Press Releases - Category: Research Source Type: news